Mölnlycke®

November 16, 2026

To our GPO partners, distributors, health systems, and customers:

We are aware of a significant market disruption affecting the availability of 2% chlorhexidine gluconate cloths. We recognize the pressure this creates for hospitals and their supply levels. To ensure product availability for our customers, we are placing the following SKUs on **allocation** effective 11/16/2026. All orders above historical averages will be evaluated individually:

- 57541
- 57504
- 59911
- 59915

Our supply management approach:

- **Prioritize current customers.** Our priority is hospitals and health systems that rely on Molnlycke today.
- **Use historical demand as the starting point.** Orders from current customers will be managed against established purchasing patterns and expected expansion. We will monitor material changes closely and coordinate with our distributor partners to limit avoidable disruption.
- **Support planned conversions already underway.** Organizations already engaged with Molnlycke on a planned, long-term conversion will be considered within existing forecasts and implementation plans, subject to confirmed availability.
- **Evaluate incremental requests carefully.** Requests from new or temporarily displaced customers will be reviewed based on product availability, requested volume, timing, clinical fit, and the ability to support implementation without putting existing customers at risk.
- **Avoid commitments we cannot reliably fulfill.** The current market gap is substantially larger than normal safety-stock levels, and our replenishment lead times are 3-4 months on most product codes. For that reason, availability may vary by product, quantity, location, and delivery date.


You can expect transparent discussions regarding realistic quantities, timing, and product options, as well as close coordination with our distributors, GPO partners, and health-system supply chain teams. Daily assessment of demand, inventory, and production signals will continue through the duration of this disruption. We also encourage our customers to collaborate closely with their distributors to ensure they are receiving the appropriate product quantities allocated.

For further support, please work with your Molnlycke representative. To accelerate review of your product need, please provide your contact with the following information: the affected facility/IDN, current product utilization, monthly quantity required, requested start date, expected duration, and preferred distributor.

We understand that supply reliability is essential to patient care. Our approach is intended to be fair and transparent, protecting current customers while offering as much help as our operations allow. We appreciate your partnership as we navigate this major disruption together.

Sincerely,

Chris Barys



Marketing Manager - Antiseptics